Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enasidenib in IDH2-mutated advanced hematologic malignancies
NCT01915498Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Aug 2013
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of enasidenib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Celgene Corporation. Started Aug 2013; status: completed.
02
Drugs
enasidenib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01915498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01915498.